EcoDrugPlus

Proteasome 20s Subunit Alpha 8

Ensembl ID : ENSBGRG00000024651
Gene Symbol: PSMA8
1 Cross references
198 Possible Orthologues:

Proteasome 20s Subunit Beta 1

Ensembl ID : ENSBGRG00000023439
Gene Symbol: PSMB1
1 Cross references
217 Possible Orthologues:

Proteasome 20s Subunit Beta 10

Ensembl ID : ENSBGRG00000023431
Gene Symbol: PSMB10
1 Cross references
172 Possible Orthologues:

Proteasome 20s Subunit Beta 2

Ensembl ID : ENSBGRG00000010708
Gene Symbol: PSMB2
1 Cross references
221 Possible Orthologues:

Proteasome 20s Subunit Beta 3

Ensembl ID : ENSBGRG00000014781
Gene Symbol: PSMB3
1 Cross references
251 Possible Orthologues:

Proteasome 20s Subunit Beta 4

Ensembl ID : ENSBGRG00000002110
Gene Symbol: PSMB4
1 Cross references
212 Possible Orthologues:

Proteasome 20s Subunit Beta 5

Ensembl ID : ENSBGRG00000005400
Gene Symbol: PSMB5
1 Cross references
221 Possible Orthologues:

Proteasome 20s Subunit Beta 7

Ensembl ID : ENSBGRG00000018037
Gene Symbol: PSMB7
1 Cross references
217 Possible Orthologues:

Proteasome 20s Subunit Beta 8

Ensembl ID : ENSBGRG00000022108
Gene Symbol: PSMB8
1 Cross references
221 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 2

Ensembl ID : ENSBGRG00000000173
Gene Symbol: PSMD2
1 Cross references
224 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 4

Ensembl ID : ENSBGRG00000001873
Gene Symbol: PSMD4
1 Cross references
287 Possible Orthologues:

Proteasome 26s Subunit, Atpase 1

Ensembl ID : ENSBGRG00000006191
Gene Symbol: PSMC1
1 Cross references
316 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).